Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE

免疫球蛋白E 免疫学 抗体 慢性荨麻疹 皮肤病科 医学
作者
Pavel Kolkhir,Elena Kovalkova,Anton A. Chernov,I V Danilycheva,Karoline Krause,Merle Sauer,A E Shulzhenko,Daria Fomina,Marcus Maurer
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:9 (11): 4138-4146.e8 被引量:67
标识
DOI:10.1016/j.jaip.2021.07.043
摘要

Autoimmune chronic spontaneous urticaria (aiCSU) comes with high disease activity and poor response to treatment. Recently, elevated levels of IgG anti-thyroid peroxidase (aTPO) and low levels of total IgE were reported to be common in aiCSU.To investigate how high aTPO and low IgE individually and combined are linked to features of aiCSU, including treatment responses.We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses. Total IgE and aTPO were measured, and 4 markers of aiCSU were analyzed: autologous serum skin test, basophil activation test (BAT), and blood eosinophil and basophil counts. Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123). aTPO↑IgE↓ was linked to higher age at CSU onset, being female, angioedema, and shorter CSU duration. aTPO↑IgE↓ was associated with markers of aiCSU, that is, BAT and autologous serum skin test positivity, basopenia, and eosinopenia (P < .01 for all). Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P < .001). Relative risk of showing BAT positivity for a patient with aTPO↑IgE↓ is 3.636 (95% CI, 2.382-5.551). Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).Our findings suggest that aTPO↑IgE↓ is a useful diagnostic marker for aiCSU in everyday clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6应助小梁要加油采纳,获得10
2秒前
2秒前
3秒前
changping应助科研通管家采纳,获得150
3秒前
CodeCraft应助科研通管家采纳,获得10
3秒前
香蕉觅云应助科研通管家采纳,获得10
3秒前
科研通AI6应助科研通管家采纳,获得10
3秒前
思源应助科研通管家采纳,获得10
3秒前
changping应助科研通管家采纳,获得150
3秒前
科研通AI6应助科研通管家采纳,获得150
3秒前
顾矜应助科研通管家采纳,获得10
3秒前
科研通AI6应助科研通管家采纳,获得150
3秒前
传奇3应助科研通管家采纳,获得30
4秒前
changping应助科研通管家采纳,获得150
4秒前
浮游应助科研通管家采纳,获得10
4秒前
科研通AI6应助科研通管家采纳,获得10
4秒前
bkagyin应助科研通管家采纳,获得10
4秒前
4秒前
浮游应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
4秒前
changping应助科研通管家采纳,获得150
4秒前
彭于晏应助科研通管家采纳,获得10
4秒前
共享精神应助科研通管家采纳,获得10
4秒前
科研通AI6应助科研通管家采纳,获得10
4秒前
科研通AI6应助科研通管家采纳,获得150
4秒前
Akim应助科研通管家采纳,获得10
4秒前
changping应助科研通管家采纳,获得150
4秒前
浮游应助科研通管家采纳,获得10
4秒前
VDC应助科研通管家采纳,获得30
4秒前
彭于晏应助科研通管家采纳,获得30
4秒前
科研通AI5应助科研通管家采纳,获得30
4秒前
sun完成签到,获得积分10
5秒前
mm发布了新的文献求助10
6秒前
李佳欣发布了新的文献求助10
6秒前
科研通AI2S应助某某采纳,获得10
7秒前
刘永红发布了新的文献求助10
8秒前
温期涵发布了新的文献求助10
9秒前
12秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5135125
求助须知:如何正确求助?哪些是违规求助? 4335681
关于积分的说明 13507506
捐赠科研通 4173285
什么是DOI,文献DOI怎么找? 2288314
邀请新用户注册赠送积分活动 1289041
关于科研通互助平台的介绍 1230093